proinsulin peptide/calcitriol liposome (ASITI-201)
/ UniQuest
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 24, 2025
Investigating the safety, tolerability and immune modulation of a novel treatment for stage 3 type one diabetes and help preserve remaining beta cells.
(ANZCTR)
- P1 | N=36 | Recruiting | Sponsor: UniQuest Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2024
Enrollment open • Trial initiation date • Diabetes • Immune Modulation • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus • HLA-DQB1
1 to 1
Of
1
Go to page
1